Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome
暂无分享,去创建一个
G. Granata | M. Luigetti | G. Primiano | V. Damato | A. Modoni | R. Iorio | A. Evoli | M. Distefano | G. Spagni | G. Monte | Bo-jian Sun | Silvia Falso
[1] J. Honnorat,et al. Autoimmune neuromyotonia , 2022, Current opinion in neurology.
[2] P. Calabresi,et al. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia , 2021, European journal of neurology.
[3] D. Bennett,et al. Leucine‐Rich Glioma‐Inactivated 1 versus Contactin‐Associated Protein‐like 2 Antibody Neuropathic Pain: Clinical and Biological Comparisons , 2021, Annals of neurology.
[4] J. Honnorat,et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes , 2021, Neurology: Neuroimmunology & Neuroinflammation.
[5] K. Claeys,et al. Neuromuscular hyperexcitability syndromes , 2021, Current opinion in neurology.
[6] Gianvito Masi,et al. Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis , 2021, Journal of Neuroimmunology.
[7] S. Aaron,et al. Utility of stimulus induced after discharges in the evaluation of peripheral nerve hyperexcitability: Old wine in a new bottle? , 2020, Journal of the peripheral nervous system : JPNS.
[8] M. Elsensohn,et al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[9] S. Irani,et al. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2 , 2020, Practical Neurology.
[10] C. Vollono,et al. Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology , 2020, European journal of neurology.
[11] A. Boon,et al. AANEM – IFCN glossary of terms in neuromuscular electrodiagnostic medicine and ultrasound , 2020, Clinical Neurophysiology.
[12] E. Marchioni,et al. Acquired neuromyotonia in thymoma‐associated myasthenia gravis: a clinical and serological study , 2019, European journal of neurology.
[13] A. Vincent,et al. Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia , 2018, JAMA neurology.
[14] J. Britton,et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2‐IgG–positive patients , 2017, Annals of neurology.
[15] A. Cebrian-Silla,et al. Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis , 2017, Neurology.
[16] A. Vincent,et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies , 2017, Journal of Neurology, Neurosurgery & Psychiatry.
[17] P. S. Sillevis Smitt,et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies , 2016, Neurology.
[18] Z. Simmons,et al. Isaacs syndrome: A review , 2015, Muscle & nerve.
[19] E. Lancaster,et al. Paraneoplastic Disorders in Thymoma Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Masahiko Watanabe,et al. Autoantibodies to Epilepsy-Related LGI1 in Limbic Encephalitis Neutralize LGI1-ADAM22 Interaction and Reduce Synaptic AMPA Receptors , 2013, The Journal of Neuroscience.
[21] S. Scherer,et al. Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. , 2013, JAMA neurology.
[22] Lyell K. Jones,et al. Cramp‐fasciculation syndrome in patients with and without neural autoantibodies , 2013, Muscle & nerve.
[23] A. Vincent,et al. Morvan syndrome: Clinical and serological observations in 29 cases , 2012, Annals of neurology.
[24] K. Strauss,et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia , 2011, Annals of neurology.
[25] A. Vincent,et al. Peripheral nerve hyperexcitability , 2011, Neurology.
[26] A. Vincent,et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.
[27] M. Benatar,et al. Accuracy of repetitive nerve stimulation for diagnosis of the cramp–fasciculation syndrome , 2007, Muscle & nerve.
[28] K. Mills,et al. Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability , 2006, Muscle & nerve.
[29] V. Lennon,et al. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability , 2002, Muscle & nerve.
[30] K. Mills,et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. , 2002, Brain : a journal of neurology.
[31] G Plazzi,et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. , 2001, Brain : a journal of neurology.
[32] L. Gutmann,et al. When is myokymia neuromyotonia? , 2001, Muscle & nerve.
[33] T. Heiman-Patterson,et al. Cramp,fasciculation syndrome , 1991, Neurology.
[34] B. Katirji. Peripheral nerve hyperexcitability. , 2019, Handbook of clinical neurology.
[35] Elio Lugaresi,et al. Agrypnia excitata. , 2011, Sleep medicine.